Anzeige
Mehr »
Mittwoch, 25.03.2026 - Börsentäglich über 12.000 News
Drohnenkrieg eskaliert - und diese Aktie greift nach zwei Mega-Märkten
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Zacks

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
Di3 Top Ranked High Growth Stocks You Can't Ignore: ROKU, TER, CRDO
DiNextEra's Federal Energy Deal Could Power Its Stock to Higher Highs
DiGilead Strengthens Inflammation Portfolio With Ouro Medicines Deal
DiVenture Global Expands LNG Portfolio, Signs New Agreement With Vitol
DiUp Over 100%: 3 High-Momentum Stocks to Buy Right Away
DiInvesting During War: Stocks, Gold, Commodities and Crypto
DiAdvanced Packaging Growth Drives KLAC's Prospects: What's Ahead?
DiSoFi vs. Nu Holdings: Which Fintech Stock Stands Out Right Now?
DiIONQ or QBTS: Which Quantum Stock Should You Hold After 2026 Sell-Off?
DiFCPT Expands Portfolio, Acquires BluePearl Pet Hospital Property
DiAFL Enhances Group Life Product With Life Insurance and LTC Combo
DiChewy to Report Q4 Earnings: Essential Insights Ahead of the Report
DiVICI Properties Expands Relationship With Cain & Eldridge Industries
DiAxon vs. Teledyne: Which Defense & Security Stock has Greater Upside?
DiKINS Outpaces Industry, Trades at a Premium: Time to Buy the Stock?
DiHL vs. PAAS: Which Silver Mining Stock has Greater Upside?
DiWill USA Rare Earth's Arnold Partnership Enhance Rare-Earth Supply Chains?
DiAVGO's Symantec CBX Expands Security Portfolio: Revenues to Surge?
DiAMD Rides on Accelerating Data Center Growth: A Sign of More Upside?
DiMastercard vs. Affirm: Which Fintech Stock Wins the Upside Race?
DiSkyWest's EPS Estimates Northbound: Should Investors Buy the Stock?
DiImmunityBio Rises on China Nod to Bladder Cancer Combo Therapy
DiApple vs. Amazon: Which AI-Driven Tech Stock Has an Edge Now?
DiSchneider's EPS Estimates Southbound: Time to Sell the Stock?
DiVALN Stock Nosedives on Mixed Results From Lyme Disease Vaccine Study